GlassScriptPhysician profile
Sara J Toth
NPI 1669022919
$8,206.58
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,092 · 2022: $3,284 · 2023: $2,618 · 2024: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,508.26 | 2021-2023 | Jardiance, Mounjaro, Lyumjev |
| Novo Nordisk INC | $1,016.79 | 2022-2023 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $577.88 | 2021-2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $518.82 | 2021-2023 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $435.90 | 2021-2023 | Farxiga |
| Amgen INC. | $435.31 | 2021-2024 | Repatha, Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $356.83 | 2021-2023 | |
| Antares Pharma, INC. | $355.47 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $344.33 | 2022-2023 | |
| Amarin Pharma, INC. | $292.70 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $277.88 | 2021-2023 | Imcivree |
| Dexcom, INC. | $260.38 | 2021-2023 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $234.30 | 2021-2023 | Unithroid |
| Lifescan, INC. | $195.75 | 2021-2023 | |
| Abbvie INC. | $144.23 | 2021-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $135.12 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $125.43 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $121.94 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $101.04 | 2021-2022 | |
| Abbott Laboratories | $90.65 | 2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $86.81 | 2021-2022 | |
| Insulet Corporation | $75.69 | 2021-2023 | Omnipod |
| Mannkind Corporation | $65.23 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $63.02 | 2021-2023 | Somatuline Depot |
| Nevro Corp. | $53.82 | 2023-2024 | Senza |
| Embecta Corp. | $51.74 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Cequr Corporation | $47.48 | 2023 | Cequr Simplicity |
| Eusa Pharma (US) LLC | $38.20 | 2022 | |
| Ascendis Pharma Endocrinology INC | $31.12 | 2023 | |
| Halozyme INC | $28.50 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.49 | 2021 | |
| Currax Pharmaceuticals LLC | $26.10 | 2021-2022 | |
| Ibsa Pharma INC. | $25.37 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.12 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.00 | 2023 | Inpefa |
| Acerus Pharmaceuticals Corporation | $17.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Toth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.